Letter: tofacitinib in treatment‐refractory ulcerative colitis—a single centre real‐world experience in Australia. Authors' reply
Open Access
- 31 July 2021
- journal article
- letter
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 54 (4) , 534-535
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Letter: tofacitinib in biologic‐experienced ulcerative colitis—a single‐centre real‐world experience in AustraliaAlimentary Pharmacology & Therapeutics, 2021
- JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinibAnnals of the Rheumatic Diseases, 2021
- Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti‐TNF‐refractory Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2020
- Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatmentAlimentary Pharmacology & Therapeutics, 2020
- The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti‐tumour necrosis factorAlimentary Pharmacology & Therapeutics, 2020
- Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registryAlimentary Pharmacology & Therapeutics, 2020
- Development and Validation of a Patient-reported Score to Screen for Mucosal Inflammation in Inflammatory Bowel DiseaseJournal of Crohn's and Colitis, 2018